PremiumCompany AnnouncementsAlgernon Pharmaceuticals Extends Warrant Expiry Date to November 2025 Psychedelic: Clearmind initiates U.S. clinical site for CMND-100 trial Algernon Pharmaceuticals receives notice of allowance from EPO for Repirinast PremiumThe FlyPsychedelic: Relmada acquires neurosteroid from Asarina Algernon Pharmaceuticals appoints Validcare as CRO for Phase 2a DMT trial Algernon Pharmaceuticals Secures Patent for Lead CKD Drug PremiumCompany AnnouncementsAlgernon Pharmaceuticals Launches Private Placement Algernon Pharmaceuticals Completes Key Funding Round Algernon Pharmaceuticals Boosts Private Placement